No Data
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | HOOKIPA Pharma Inc - Initial Safety and Efficacy Data From Iit Expected in 2026
HOOKIPA Pharma Doses First Patients With Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
Express News | HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
No Data
No Data